Coherus BioSciences Provides Update on ‘619 IPR Institution Decision
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
IPR Decision Disappointing for Coherus Biosciences (CHRS) But Focus Remains on Neulasta - Cowen
September 7, 2017 1:46 PM EDTCowen analyst Ken Cacciatore weighs in on Coherus Biosciences (NASDAQ: CHRS) following an adverse IPR decision on the Humira '619 patents.
Cacciatore said while this is disappointing, their focus remains on biosimilar Neulasta and the hopeful year-end BLA re-filing.
The firm... More
